Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26‐week randomized, open‐label, treat‐to‐target non‐inferiority trial
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Aims: The efficacy and safety of insulin degludec ( IDeg ) was compared with insulin detemir ( IDet ), both administered once daily ( OD ) as basal treatment in participants with type 1 diabetes mellitus ( T1DM ). The primary outcome was non‐inferiority of IDeg to IDet in glycated haemoglobin ( HbA1c ) reduction after 26 weeks. Methods: This multinational, 26‐week, controlled, open‐label, parallel‐group trial randomized adults with T1DM to IDeg or IDet as OD basal insulin treatment combined with mealtime bolus insulin aspart ( IAsp ). Participants with T1DM treated with any basal–bolus insulin regimen for ≥12 months prior to the trial, a mean HbA1c ≤ 10.0% (85.8 mmol/mol) and body mass index ( BMI ) ≤35.0 kg/m 2 at screening participated in the trial ( IDeg : N = 302; IDet : N = 153). Results: After 26 weeks, HbA1c decreased 0.73% (8.0 mmol/mol) ( IDeg ) and 0.65% (7.1 mmol/mol) ( IDet ) [estimated treatment difference ( ETD ) IDeg–IDet : −0.09% (−0.23; 0.05) 95% CI (−10.0 mmol/mol [−2.6; 0.6] 95% CI ); confirming non‐inferiority]. Mean fasting plasma glucose improved in both groups, and was lower with IDeg than IDet [ ETD IDeg–IDet : −1.66 mmol/l (−2.37; −0.95) 95% CI , p < 0.0001]. The rate of confirmed hypoglycaemia was similar with IDeg and IDet [45.83 vs. 45.69 episodes per patient‐year of exposure ( PYE ); estimated rate ratio ( RR ) IDeg / IDet : 0.98 (0.80; 1.20) 95% CI , p = 0.86]. The rate of nocturnal confirmed hypoglycaemia was lower with IDeg than IDet [4.14 vs. 5.93 episodes per PYE ; RR IDeg / IDet : 0.66 (0.49; 0.88) 95% CI , p = 0.0049]. Adverse event profiles were similar between groups. Conclusion: IDeg administered OD in basal–bolus therapy effectively improved long‐term glycaemic control in participants with T1DM with a lower risk of nocturnal confirmed hypoglycaemia than IDet .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448
Bolli, G., Feo, P. D., Compagnucci, P., Cartechini, M. G., Angeletti, G., Santeusanio, F., Brunetti, P., & Gerich, J. E. (1983) · Diabetes · doi:10.2337/diab.32.2.134 · Cited by 433
Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60204-9 · Cited by 402 · cited 15×
“This mirrors the results from a comparison of IDeg and IGlar in participants with T1DM [22].”
BackgroundResultInfluentialHeise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397 · cited 1×
“The lower rate of nocturnal hypoglycaemia associated with IDeg compared to IDet and IGlar could be explained by the more consistent pharmacokinetic and pharmacodynamic profile of IDeg, namely the longer duration of action as well as lower day-to-day and hour-to-hour pharmacodynamic variability [16,33].”
BackgroundUltra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes
Heise, T., Nosek, L., Bøttcher, S. G., Hastrup, H., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01638.x · Cited by 331 · cited 1×
“This results in a stable and consistent glucose-lowering effect of >42 h at steady state [16–20] and lower rates of hypoglycaemia than IGlar [21–23].”
BackgroundThe impact of non-severe hypoglycemic events on work productivity and diabetes management
Brod, M., Christensen, T., Thomsen, T. L., & Bushnell, D. M. (2011) · Value in Health · doi:10.1016/j.jval.2011.02.001 · Cited by 284 · cited 1×
“affecting many aspects of patient well-being that can reduce treatment adherence and lead to suboptimal glycaemic control [4–7].”
BackgroundDavis, E. A., Keating, B., Byrne, G. C., Russell, M., & Jones, T. W. (1997) · Diabetes Care · doi:10.2337/diacare.20.1.22 · Cited by 273 · cited 1×
“Moreover, people with T1DM have impaired plasma epinephrine responses to hypoglycaemia, with an increased risk of severe hypoglycaemia, especially during sleep [8,9].”
BackgroundKlein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L., & Heise, T. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00685.x · Cited by 251 · cited 1×
“IDet and IGlar have similar time–action profiles [13] and produce similar levels of glycaemic control [14], but IDet”
BackgroundMathieu, C., Hollander, P., Miranda-Palma, B., Cooper, J., Franek, E., Russell-Jones, D., Larsen, J., Tamer, S. C., Bain, S. C., & on behalf of the NN1250-3770 (BEGIN: Flex T1) Trial Investigators (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3249 · Cited by 219
Bartley, P. C., Bogoev, M., Larsen, J., & Philotheou, A. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02407.x · Cited by 159 · cited 1×
“The level of overall glycaemic control (HbA1c) obtained with IDeg and IDet in this trial was comparable to that achieved in previous treat-to-target trials with IDet at a similar treatment regimen [10,14].”
Result
Cited by
Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
Janež, A., Guja, C., Mitrakou, A., Lalic, N., Tankova, T., Czupryniak, L., Tabák, A. G., Prazny, M., Martinka, E., & Smircic-Duvnjak, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00743-7 · Cited by 177
Russell-Jones, D., Babazono, T., Cailleteau, R., Engberg, S., Irace, C., Kjaersgaard, M. I. S., Mathieu, C., Rosenstock, J., Woo, V., & Klonoff, D. C. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02179-7 · Cited by 115
Thalange, N., Deeb, L., Iotova, V., Kawamura, T., Klingensmith, G., Philotheou, A., Silverstein, J., Tumini, S., Ocampo Francisco, A., Kinduryte, O., et al. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12263 · Cited by 91
Kazda, C. M., Bue-Valleskey, J. M., Chien, J., Zhang, Q., Chigutsa, E., Landschulz, W., Wullenweber, P., Haupt, A., & Dahl, D. (2023) · Diabetes Care · doi:10.2337/dc22-2395 · Cited by 56
“The basis for the selection of such conservative titration algorithms was another 26-week treat-to-target study comparing degludec with detemir using a very aggressive titration algorithm with a fasting glucose target of 70–89 mg/dL and no mandatory basal insulin reductions for hypoglycemic events (12).”
Background(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus
Hemmingsen, B., Metzendorf, M.-I., & Richter, B. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013498.pub2 · Cited by 37
Metadata
- Authors
- Davies, M. J., Gross, J. L., Ono, Y., Sasaki, T., Bantwal, G., Gall, M. A., Niemeyer, M., Seino, H., & on behalf of the BEGIN BB T1 study group
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-05-08
- Volume
- 16
- Issue
- 10
- Pages
- 922-930
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2092860355
- Cited by
- 53
- References
- 13
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.